Risankizumab
List of Advanced Rx Recommended For Moderate to Severe UC Expands
The AGA has released an updated guideline on pharmacologic management of adult outpatients with UC that, for the ...
FEBRUARY 4, 2025
Risankizumab and Tulisokibart for Ulcerative Colitis
We rarely discuss early trials, but this month we highlight a phase 2 trial that offers a promising new mechanism ...
JANUARY 23, 2025
Approach to Older Adults With Moderate To Severe Crohn’s Disease
The incidence and prevalence of inflammatory bowel disease are rising worldwide, particularly in older adults.
DECEMBER 23, 2024
New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC
The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...
NOVEMBER 26, 2024
Head-to-Head IL Inhibitors, SPICY Trial Surgical Techniques in CD
In this edition of The Regueiro Report, I highlight a head-to-head comparison of two drugs and another study ...
OCTOBER 16, 2024
The ABCs of Optimizing Drug Sequencing for IBD
The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...
OCTOBER 13, 2024
Combination Advanced Therapy in the Treatment of Inflammatory Bowel Disease
The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...
SEPTEMBER 5, 2024
Good News for Maintenance Therapies in IBD
Both studies in this month’s The Regueiro Report are about interleukin inhibitors: risankizumab and ...
JULY 16, 2024
Expert Picks From DDW 2024, Part 1: IBD, EoE, NERD and More
In this installment of Expert Picks from DDW 2024, Anisa Shaker, MD, discusses five of her favorite abstracts and ...
JULY 12, 2024
FDA Approves Risankizumab for Ulcerative Colitis
The FDA has approved risankizumab (Skyrizi, AbbVie) for patients with moderate to severe ulcerative colitis.
JUNE 26, 2024
Miguel Regueiro, MD, Picks His Favorite IBD Research From DDW 2024
Digestive Disease Week 2024 was overflowing with research on all GI topics.
MAY 30, 2024
Equipoise at Risk With Placebo-Controlled Trials
The standard approach to randomized clinical trials for moderate to severe IBD causes harm to participants, ...
MAY 21, 2024
